217,800 Shares in Artivion, Inc. (NYSE:AORT) Bought by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC bought a new stake in shares of Artivion, Inc. (NYSE:AORT) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 217,800 shares of the company’s stock, valued at approximately $5,798,000. Lord Abbett & CO. LLC owned approximately 0.52% of Artivion as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. nVerses Capital LLC purchased a new position in shares of Artivion during the 2nd quarter valued at about $28,000. Quarry LP lifted its holdings in Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after purchasing an additional 820 shares in the last quarter. RiverPark Advisors LLC bought a new position in shares of Artivion in the second quarter worth approximately $55,000. RW Investment Management LLC purchased a new stake in shares of Artivion in the second quarter worth $219,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Artivion in the second quarter worth $253,000. Institutional investors own 86.37% of the company’s stock.

Insider Buying and Selling

In other news, SVP Jean F. Holloway sold 8,070 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at $4,634,323.44. This represents a 4.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,447 shares of company stock worth $925,424. Corporate insiders own 8.10% of the company’s stock.

Artivion Stock Up 0.1 %

AORT opened at $28.96 on Tuesday. The company has a market capitalization of $1.21 billion, a PE ratio of -1,448.00 and a beta of 1.75. The firm has a 50-day simple moving average of $27.70 and a two-hundred day simple moving average of $26.24. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 52 week low of $16.48 and a 52 week high of $30.45.

Analyst Ratings Changes

A number of research firms recently weighed in on AORT. JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research note on Tuesday, December 10th. Oppenheimer boosted their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Needham & Company LLC reiterated a “buy” rating and set a $34.00 target price on shares of Artivion in a research report on Monday, December 9th. Finally, Stifel Nicolaus lifted their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Artivion currently has an average rating of “Buy” and a consensus price target of $31.80.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.